ArticleJournal of molecular histology2025
Gallic acid enhanced reproductive function by modulating oxidative stress mediators in gentamicin-treated rats.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hesperidin attenuates gentamicin-induced testicular toxicity via modulation of the PI3K/AKT signaling pathway.BMC complementary medicine and therapies · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gentamicin (GEN), commonly used to treat gram-negative bacterial infections, can cause testicular damage, maybe by increasing oxidative stress. Gallic acid (GA) a polyphenolic acid, has antioxidant, anti-bacterial, anti-viral, and anti-allergic activities. The study aimed to investigate the effects of GA on GEN-induced testicular toxicity. Thirty Wistar rats were randomly divided into five groups: Control, which received only normal saline, and GEN, which received 100 mg/kg/day of GEN intra-peritoneally for six days. The rats in groups 3, 4, and 5 received GA by gavage at 60, 90, and 120 mg/kg for 14 consecutive days and six intraperitoneal injections of 100 mg/kg/day of GEN from nine to fourteen days, respectively. After the last treatment, rats were sacrificed, and testicular weights, sperm parameters (viability, number, and motility of sperm), serum testosterone and gonadotropin hormones, tissue superoxide dismutase and malondialdehyde, and testicular histology were evaluated. Gentamicin reduced sperm count, viability, motility, and testicular-weight, as well as serum levels of testosterone, FSH, LH, and SOD. Testicular-weight in GEN + 60, 90, and 120 mg/kg GA groups had significantly increased compared to GEN group. All GA doses in the GEN + GA groups, increased FSH (except dose of 60), LH and testosterone (p < 0.05). In the rats received 120 mg/kg GA, MDA decreased and SOD increased significantly (p < 0.05). Histopathological findings showed that the administration of GA could significantly reduce the adverse effects of GEN on the structure of seminiferous tubules and the number of germ cells (p < 0.05). Administration of GA adjunct with GEN might be beneficial in men who were under GEN therapy.
Indexed as
Identifiers
40879798What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.